The impact of invasive fungal diseases on survival after lung transplantation

Clinical Transplantation

Volumn 24, Issue 3, 2010, Pages 341-348

  Arthurs, Supha K ^a   Eid, Albert J ^a   Deziel, Paul J ^b   Marshall, William F ^b   Cassivi, Stephen D ^c   Walker, Randall C ^b   Razonable, Raymund R ^b  

^a Division of Infectious Diseases   (United States)

^b William J von Liebig Transplant Center   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Aspergillosis; Cytomegalovirus; Fungemia; Infection; Lung transplantation; Mycoses; Survival

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AZATHIOPRINE; CEFOTAXIME; CYCLOSPORIN; DAPSONE; FLUCONAZOLE; GANCICLOVIR; HYPERIMMUNE GLOBULIN; ITRACONAZOLE; METHYLPREDNISOLONE; OKT 3; PENTAMIDINE; PREDNISONE; SULFAMETHOXAZOLE; TRIMETHOPRIM; VALGANCICLOVIR;

ADULT; ARTICLE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; SYSTEMIC MYCOSIS; CAUSE OF DEATH; MIDDLE AGED; MYCOSIS; OPPORTUNISTIC INFECTION; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

CAUSE OF DEATH; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 77954162280     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01076.x     Document Type: Article

References (37)

1. Christie JD, Edwards LB, Aurora P. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report--2008. J Heart Lung Transplant 2008, 27:957.
2. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001, 3:128.
3. Avery RK. Infections after lung transplantation. Semin Respir Crit Care Med 2006, 27:544.
4. Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remington JS. Infectious complications in heart-lung transplant recipients. Am J Med 1985, 79:412.
5. Frost AE. Role of infections, pathogenesis, and management in lung transplantation. Transplant Proc 1999, 31:175.
6. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094.
7. Paya C, Humar A, Dominguez E. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4:611.
8. Humar A, Hebert D, Davies HD. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006, 81:856.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373.
10. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002, 40:746.
11. De Pauw B, Walsh TJ, Donnelly JP. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813.
12. Arthurs SK, Eid AJ, Pedersen RA. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008, 46:840.
13. Limaye AP, Bakthavatsalam R, Kim HW. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006, 81:1645.
14. Humar A, Kumar D, Preiksaitis J. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005, 5:1462.
15. Zamora MR, Nicolls MR, Hodges TN. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004, 4:1635.
16. Valentine VG, Bonvillain RW, Gupta MR. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant 2008, 27:528.
17. Danziger-Isakov LA, Worley S, Arrigain S. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant 2008, 27:655.
18. Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amitai Z, Theodore J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993, 153:2010.
19. Maurer JR, Tullis DE, Grossman RF, Vellend H, Winton TL, Patterson GA. Infectious complications following isolated lung transplantation. Chest 1992, 101:1056.
20. Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993, 8:207.
21. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996, 61:915.
22. Iversen M, Burton CM, Vand S. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007, 26:879.
23. Sole A, Morant P, Salavert M, Peman J, Morales P. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005, 11:359.
24. Brenier-Pinchart MP, Lebeau B, Devouassoux G. Aspergillus and lung transplant recipients: a mycologic and molecular epidemiologic study. J Heart Lung Transplant 1998, 17:972.
25. Cahill BC, Hibbs JR, Savik K. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997, 112:1160.
26. Husain S, Paterson DL, Studer S. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006, 6:3008.
27. Nunley DR, Ohori P, Grgurich WF. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998, 114:1321.
28. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007, 45:305.
29. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003, 22:258.
30. Yeldandi V, Laghi F, McCabe MA. Aspergillus and lung transplantation. J Heart Lung Transplant 1995, 14:883.
31. Minari A, Husni R, Avery RK. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002, 4:195.
32. Herbrecht R, Denning DW, Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408.
33. Walsh TJ, Lutsar I, Driscoll T. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002, 21:240.
34. Walsh TJ, Raad I, Patterson TF. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2.
35. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006, 8:213.
36. Ustun C, Farrow S, DeRemer D, Fain H, Jillella AP. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:807.
37. Groetzner J, Kaczmarek I, Wittwer T. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008, 27:1.